Singapore, May 12, 2008: Australia’s Helicon group has said that it has acquired the exclusive licensing rights from EUSA Pharma to Collatamp G for the Chinese market.

 

Collatamp G is an implantable collagen based device that contains and delivers to the surgical site the proven and effective antibiotic, Gentamycin.

 

Helicon Group CEO Peter Abrahamson stated that the company's research indicated there was a potentially sizeable market for Collatamp G in China.

 

"The EUSA licensing deal is a very significant event for the company and an important addition to our innovative surgical products portfolio," said Abrahamson.

 

In controlled clinical trials Collatamp G has been shown to significantly reduce the incidence of severe post surgical infections whilst minimizing the risk of toxicity and the associated side effects of systemic Gentamycin. This in turn leads to faster recuperation.

 

The product remains inside the body post surgery and, over a period of 7-10 days, the collagen is safely absorbed by the body whilst releasing the antibiotic at the site of potential infection.

 

It can be utilized across a wide range of surgeries but it is especially valuable in patients with a high risk of infection, for example, orthopedic, vascular, cardio thoracic and abdominal surgery.

 

Collatamp G also functions as an exterior wound dressing and has been shown to, for example, control severe infections in diabetic foot ulcers thereby significantly reducing the likelihood of amputation.

 

The deal with EUSA Pharma, a rapidly expanding pharmaceutical company focusing primarily on Europe and the USA, also provides Helicon with first right of refusal for new products that the company develops or acquires.